An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) is set to present at the 23rd Annual Needham Virtual Healthcare Conference, offering a company overview on April 9, 2024. The presentation will be available via live audio webcast on the company's website, with a replay option post-event.
Positive
None.
Negative
None.
FRIENDSWOOD, Texas--(BUSINESS WIRE)--
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 12:45 p.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available following the conclusion of the live broadcast.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
When is Castle Biosciences, Inc. (CSTL) presenting at the 23rd Annual Needham Virtual Healthcare Conference?
Castle Biosciences, Inc. (CSTL) is presenting at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024.
What time is Castle Biosciences, Inc. (CSTL) scheduled to present at the conference?
Castle Biosciences, Inc. (CSTL) is scheduled to present at 12:45 p.m. Eastern time.
Where can I access the live audio webcast of Castle Biosciences, Inc. (CSTL) presentation?
The live audio webcast of Castle Biosciences, Inc. (CSTL) presentation will be available on the company's website at https://ir.castlebiosciences.com/events-presentations/default.aspx.
Will there be a replay option for Castle Biosciences, Inc. (CSTL) presentation?
Yes, a replay of the webcast will be available after the live broadcast concludes.
castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.
